Highlights
– In a prespecified interim analysis of the phase 3 ORIGIN trial, atacicept produced a 45.7% reduction in 24-hour urinary protein-to-creatinine ratio (UPCR) versus 6.8% with placebo at week 36 (between-group difference 41.8 percentage points; 95% CI, 28.9–52.3; P < 0.001).
– Three additional investigational agents—sibeprenlimab, cemdisiran, and felzartamab—reported phase 2 data showing meaningful antiproteinuric effects, but these data are smaller, of variable duration, and do not yet provide definitive evidence on kidney outcomes or long-term safety.
